This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nymox NX-1207 BPH And Prostate Cancer Symposium At American Urological Association Annual Meeting May 5 In San Diego

HASBROUCK HEIGHTS, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for Prostate Cancer. The symposium will be held during the 2013 Annual Meeting of the American Urological Association in San Diego CA 3:00 p.m. May 5 in the San Diego Convention Center.

The symposium, "Clinical studies of NX-1207: Phase 3 Injectable for BPH (Phase 2 for Prostate Cancer)," will be chaired by Ronald Tutrone Jr, MD, FACS of Towson, MD, who has participated in four of the prospective NX-1207 clinical trials as well as follow-up studies. Dr. Tutrone will present the latest information about NX-1207 and the NX-1207 clinical trials to date, including the two Phase 3 BPH clinical trials, and the Phase 2 prostate cancer trials currently in progress.

There will be seven symposium panelists who are distinguished Board-certified urologists with extensive experience as clinical investigators in FDA-regulated clinical trials, including the NX-1207 clinical trials.

Further information concerning the NX-1207 Symposium will follow separately in the near future.

NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and Phase 2 for localized prostate cancer. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7½ years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs